We are grateful to our independent panel of experts who bring specialized knowledge and experience in healthcare, advocacy, as well as a global perspective to our program.
Eric Low has worked in the field of medical research charities for over 20 years. He founded Myeloma UK in 1996, leading the organisation as Chief Executive until 2017.
He currently runs a consultancy business specialising primarily in strategic market access, life sciences and healthcare policy, patient and patient group engagement.
Eric is committed and focused on improving patient outcomes and puts patients at the centre of everything he does. His goal is to have made a significant and material impact on the quality of life of patients and the prevention and curability of rare diseases. He has a strong track record of delivery and success in building multi-stakeholder research collaborations and consortia, and in delivering innovative solutions to complex issues, challenges and barriers standing in the way of progress.
Eric is also a Senior Visiting Research fellow at the University of Leeds Medical School, and he holds several Board, honorary, advisory and voluntary positions. He also advises numerous medical and health-focused charities on a pro bono basis. He was awarded an OBE for services to charity in the Queen’s Birthday Honours 2012.
Elisa S. Weiss, Ph.D., is Senior Vice President, Patient Access and Outcomes at The Leukemia & Lymphoma Society (LLS). In this role, she oversees the development, implementation and assessment of patient and professional education initiatives, as well as LLS’s Information Resource Center, Clinical Trial Support Center, all field outreach and support, and a number of psychosocial and health services research projects. She is a medical sociologist by training, with 25 years of experience conducting health research, as well as designing and evaluating health promotion programs in both the academic and private sectors. Prior to joining LLS six years ago, Dr. Weiss’s work focused on identifying ways to enhance access to and utilization of cancer prevention services among underserved groups, and on improving the quality and accessibility of cancer treatment services, particularly clinical trials. She has extensive experience developing and evaluating multi-sector partnerships to improve health outcomes, and has developed unique measures to assess the functioning of partnerships and patients’ experiences in care. Dr. Weiss has held faculty positions at Memorial Sloan-Kettering Cancer Center and the Montefiore-Einstein Center for Cancer Care, and she has been the lead investigator on research grants to address health disparities, funded by the National Cancer Institute and the Patient-Centered Outcomes Research Institute. Dr. Weiss received her undergraduate and graduate degrees from Columbia University in New York City.
Kevin Loth, Vice President, Corporate Affairs and Policy, Worldwide Markets has worked at Celgene since 2007. He is responsible for leading Celgene’s Corporate Affairs and Policy Department, encompassing the functions of Communications, Government Relations and Patient Advocacy. Kevin is a member of the Europe and International Operating Team (EIOT) and Global Corporate Affairs Leadership Team. Kevin’s role is to lead the Worldwide Market, Corporate Affairs Community of Practice; ensuring patients remain at the centre of decision making, supporting Celgene’s growth, and promoting the value of innovation.
Kevin is the Chair of the IFPMA Rare Disease Working Group. Kevin was the former Vice-Chair of the EBE-EuropaBio Joint Taskforce on Rare Diseases and Orphan Medicinal Products and was an industry representative on the European Union Committee of Experts on Rare Diseases from 2011 to 2013. These positions have helped establish Celgene as a respected stakeholder, working in collaboration with others to improve patient access to treatments for rare, life threatening and serious debilitating diseases.
Prior to joining Celgene, Kevin spent seven years at Novartis; three years as Head of UK Government Relations and four years as Director of European Government Affairs, based in Brussels. During this time, he was responsible for managing relationships with the European Parliament, European Commission, as well as the official representatives of EU Member States.
Kevin has a PhD in Environmental Epidemiology from Imperial College, London and an MBA from Manchester Business School. His MBA thesis was on the impact of NICE on the European pharmaceutical industry.